Suppr超能文献

氢吗啡酮疗效及治疗方案对耐受性和μ-阿片受体调节的影响。

Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.

作者信息

Kumar Priyank, Sunkaraneni Soujanya, Sirohi Sunil, Dighe Shveta V, Walker Ellen A, Yoburn Byron C

机构信息

Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA.

出版信息

Eur J Pharmacol. 2008 Nov 12;597(1-3):39-45. doi: 10.1016/j.ejphar.2008.08.025. Epub 2008 Aug 30.

Abstract

This study examined the antinociceptive (analgesic) efficacy of hydromorphone and hydromorphone-induced tolerance and regulation of mu-opioid receptor density. Initially s.c. hydromorphone's time of peak analgesic (tail-flick) effect (45 min) and ED50 using standard and cumulative dosing protocols (0.22 mg/kg, 0.37 mg/kg, respectively) were determined. The apparent analgesic efficacy (tau) of hydromorphone was then estimated using the operational model of agonism and the irreversible mu-opioid receptor antagonist clocinnamox. Mice were injected with clocinnamox (0.32-25.6 mg/kg, i.p.) and 24 h later, the analgesic potency of hydromorphone was determined. The tau value for hydromorphone was 35, which suggested that hydromorphone is a lower analgesic efficacy opioid agonist. To examine hydromorphone-induced tolerance, mice were continuously infused s.c. with hydromorphone (2.1-31.5 mg/kg/day) for 7 days and then morphine cumulative dose response studies were performed. Other groups of mice were injected with hydromorphone (2.2-22 mg/kg/day) once, or intermittently every 24 h for 7 days. Twenty-four hours after the last injection, mice were tested using morphine cumulative dosing studies. There was more tolerance with infusion treatments compared to intermittent treatment. When compared to higher analgesic efficacy opioids, hydromorphone infusions induced substantially more tolerance. Finally, the effect of chronic infusion (31.5 mg/kg/day) and 7 day intermittent (22 mg/kg/day) hydromorphone treatment on spinal cord mu-opioid receptor density was determined. Hydromorphone did not produce any change in mu-opioid receptor density following either treatment. These results support suggestions that analgesic efficacy is correlated with tolerance magnitude and regulation of mu-opioid receptors when opioid agonists are continuously administered. Taken together, these studies indicate that analgesic efficacy and treatment protocol are important in determining tolerance and regulation of mu-opioid receptors.

摘要

本研究考察了氢吗啡酮的抗伤害感受(镇痛)效能、氢吗啡酮诱导的耐受性以及μ-阿片受体密度的调节。最初,通过标准给药方案和累积给药方案(分别为0.22mg/kg、0.37mg/kg)确定了皮下注射氢吗啡酮的镇痛(甩尾)效应峰值时间(45分钟)和半数有效剂量(ED50)。然后,使用激动作用操作模型和不可逆的μ-阿片受体拮抗剂氯辛那明来估计氢吗啡酮的表观镇痛效能(τ)。给小鼠腹腔注射氯辛那明(0.32 - 25.6mg/kg),24小时后,测定氢吗啡酮的镇痛效力。氢吗啡酮的τ值为35,这表明氢吗啡酮是一种镇痛效能较低的阿片类激动剂。为了考察氢吗啡酮诱导的耐受性,给小鼠连续7天皮下输注氢吗啡酮(2.1 - 31.5mg/kg/天),然后进行吗啡累积剂量反应研究。其他组小鼠分别单次注射氢吗啡酮(2.2 - 22mg/kg/天),或每24小时间歇注射7天。最后一次注射24小时后,使用吗啡累积给药研究对小鼠进行测试。与间歇治疗相比,输注治疗产生的耐受性更强。与镇痛效能较高的阿片类药物相比,氢吗啡酮输注诱导的耐受性明显更强。最后,确定了慢性输注(31.5mg/kg/天)和7天间歇性(22mg/kg/天)氢吗啡酮治疗对脊髓μ-阿片受体密度的影响。两种治疗后,氢吗啡酮均未引起μ-阿片受体密度的任何变化。这些结果支持了以下观点:当持续给予阿片类激动剂时,镇痛效能与耐受性程度以及μ-阿片受体的调节相关。综上所述,这些研究表明镇痛效能和治疗方案在确定μ-阿片受体的耐受性和调节方面很重要。

相似文献

1
Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.
Eur J Pharmacol. 2008 Nov 12;597(1-3):39-45. doi: 10.1016/j.ejphar.2008.08.025. Epub 2008 Aug 30.
2
Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
Eur J Pharmacol. 2007 Jun 1;563(1-3):92-101. doi: 10.1016/j.ejphar.2007.01.059. Epub 2007 Feb 8.
3
[(35)S]GTPγS binding and opioid tolerance and efficacy in mouse spinal cord.
Pharmacol Biochem Behav. 2012 Mar;101(1):155-65. doi: 10.1016/j.pbb.2011.11.001. Epub 2011 Nov 12.
4
Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
Brain Res. 2006 Apr 14;1083(1):61-9. doi: 10.1016/j.brainres.2006.01.095. Epub 2006 Mar 10.
5
Magnitude of tolerance to fentanyl is independent of mu-opioid receptor density.
Eur J Pharmacol. 1997 Jan 29;319(2-3):225-8. doi: 10.1016/s0014-2999(96)00960-0.
7
The analgesic efficacy of fentanyl: relationship to tolerance and mu-opioid receptor regulation.
Pharmacol Biochem Behav. 2008 Nov;91(1):115-20. doi: 10.1016/j.pbb.2008.06.019. Epub 2008 Jun 30.
9
Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors.
Eur J Pharmacol. 2007 Oct 1;571(2-3):129-37. doi: 10.1016/j.ejphar.2007.06.001. Epub 2007 Jun 12.

引用本文的文献

1
Evolution of Patient-Controlled Analgesia: From Intravenous to Sublingual Treatment.
Hosp Pharm. 2016 Mar;51(3):214-229. doi: 10.1310/hpj5103-214. Epub 2016 Mar 1.
2
Cellular Tolerance Induced by Chronic Opioids in the Central Nervous System.
Front Syst Neurosci. 2022 Jun 28;16:937126. doi: 10.3389/fnsys.2022.937126. eCollection 2022.
4
Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids.
PLoS One. 2019 Jun 6;14(6):e0217371. doi: 10.1371/journal.pone.0217371. eCollection 2019.
5
Analgesic Efficacy and Safety of Hydromorphone in Chinchillas ().
J Am Assoc Lab Anim Sci. 2018 May 1;57(3):282-285.
6
Identification of the First Marine-Derived Opioid Receptor "Balanced" Agonist with a Signaling Profile That Resembles the Endorphins.
ACS Chem Neurosci. 2017 Mar 15;8(3):473-485. doi: 10.1021/acschemneuro.6b00167. Epub 2016 Nov 22.
8
Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.
Pharmacol Rev. 2013 Jan 15;65(1):223-54. doi: 10.1124/pr.112.005942. Print 2013 Jan.
9
Differences between opioids: pharmacological, experimental, clinical and economical perspectives.
Br J Clin Pharmacol. 2013 Jan;75(1):60-78. doi: 10.1111/j.1365-2125.2012.04317.x.

本文引用的文献

2
The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence.
Curr Opin Neurobiol. 2007 Oct;17(5):556-64. doi: 10.1016/j.conb.2007.10.004. Epub 2007 Dec 18.
3
Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors.
Trends Pharmacol Sci. 2007 Aug;28(8):407-15. doi: 10.1016/j.tips.2007.06.009. Epub 2007 Jul 13.
4
Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
Eur J Pharmacol. 2007 Jun 1;563(1-3):92-101. doi: 10.1016/j.ejphar.2007.01.059. Epub 2007 Feb 8.
6
Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats.
J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201. doi: 10.1124/jpet.105.094276. Epub 2005 Nov 16.
7
Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
J Pain. 2005 Oct;6(10):662-72. doi: 10.1016/j.jpain.2005.05.004.
8
Morphine promotes rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal neurons.
J Neurosci. 2005 Aug 24;25(34):7847-57. doi: 10.1523/JNEUROSCI.5045-04.2005.
9
Hydromorphone.
J Pain Symptom Manage. 2005 May;29(5 Suppl):S57-66. doi: 10.1016/j.jpainsymman.2005.01.007.
10
Receptor endocytosis counteracts the development of opioid tolerance.
Mol Pharmacol. 2005 Jan;67(1):280-7. doi: 10.1124/mol.104.004994. Epub 2004 Oct 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验